Systemic Lupus Erythematosus (SLE) Clinical Trials

Find Systemic Lupus Erythematosus (SLE) Clinical Trials Near You

A Phase 3, Randomized, Double-Blind,Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants With Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care (ELOWEN-2)

Status: Recruiting
Location: See all (55) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration: Up to 35 weeks. Treatment Duration: 24 weeks. Visit Frequency: every 4 weeks, with the exception of the Week 2 televisit. Study Intervention Name: Enpatoran, Placebo. Intervention Form: Film-coated tablet.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Vaccinations are up to date according to local guidelines/recommendations. Recombinant zoster vaccination is encouraged but not mandatory.

• Participants with diagnosis of Discoid Lupus Erythematosus (DLE) and/or Subacute Cutaneous Lupus Erythematosus (SCLE) documented in medical history, with or without Systemic Lupus Erythematosus (SLE).

• Participants with active Acute Cutaneous Lupus Erythematosus (ACLE) as sole cutaneous manifestations is allowed in the presence of SLE and should be present for at least 6 weeks prior to the Screening visit.

• Participants with diagnosis of SLE fulfilling the European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) 2019 classification criteria, must have active DLE and/or SCLE and/or ACLE.

⁃ For participants with SLE:

• Participants with diagnosis of SLE and fulfill EULAR/ACR 2019 classification criteria.

• Participants with disease duration (cutaneous disease and, where applicable, SLE) of \>= 6 months from time of diagnosis to Screening.

• Participants with CLASI-A score \>= 8 at Screening and Day 1 visits.

• Other protocol-defined inclusion criteria may apply.

Locations
United States
California
Inland Rheumatology Clinical Trials, Inc.
RECRUITING
Upland
Florida
Omega Research Debary, LLC
RECRUITING
Debary
Centre for Rheumatology, Immunology and Arthritis
RECRUITING
Fort Lauderdale
South Florida Rheumatology
RECRUITING
Hollywood
GTL Medical And Research Group
RECRUITING
Miami
Bolanos Clinical Research
RECRUITING
Pembroke Pines
Vantage Clinical Trials
RECRUITING
Tampa
Indiana
Dawes Fretzin Clinical Research Group, LLC
RECRUITING
Indianapolis
Louisiana
Accurate Clinical Research Inc. - Lake Charles
RECRUITING
Lake Charles
Michigan
Oakland Hills Dermatology
RECRUITING
Auburn Hills
North Carolina
Arthritis and Osteoporosis Consultants of the Carolinas II, LLC
RECRUITING
Charlotte
Superior Clinical Research, LLC
RECRUITING
Smithfield
Texas
North Texas Center for Clinical Research
RECRUITING
Frisco
Accurate Clinical Research
RECRUITING
Humble
Other Locations
Australia
Monash Medical Centre Clayton
RECRUITING
Clayton
Brazil
L2IP - Instituto de Pesquisas Clínicas Ltda.
RECRUITING
Brasília
A2Z Clinical Centro Avancado de Pesquisa Clinica
RECRUITING
Campinas
Hospital Alemão Oswaldo Cruz
RECRUITING
São Paulo
RDSS Ricardo Diaz Scientific Solution
RECRUITING
São Paulo
Bulgaria
DCC 1 Sevlievo EOOD
RECRUITING
Sevlievo
DCC Alexandrovska, EOOD
RECRUITING
Sofia
Canada
The Medical Arts Health Research Group - 300128547
RECRUITING
Kelowna
China
The First Affiliated Hospital of Baotou Medical College
RECRUITING
Baotou
The First Hospital of Jilin University
RECRUITING
Changchun
West China Hospital, Sichuan University
RECRUITING
Chengdu
Fujian Provincial Hospital
RECRUITING
Fuzhou
Nanfang Hospital of Southern Medical University - 300165627
RECRUITING
Guangzhou
Qilu Hospital of Shandong University - 300163463
RECRUITING
Jinan
The First Affiliated Hospital of Henan University of Science and Technology
RECRUITING
Luoyang
Nanjing Drum Tower Hospital
RECRUITING
Nanjing
The Second Hospital of Hebei Medical University - 300184836
RECRUITING
Shijiazhuang
The Second Affiliated Hospital of Soochow University
RECRUITING
Suzhou
Germany
Universitaetsklinikum Leipzig AoeR - Klinik u. Polikl. f.Dermatol.,Venerol. u. Allergol
RECRUITING
Leipzig
Klinikum Oldenburg AoeR - Universitatsklinik f Dermatologie u. Allergologie
RECRUITING
Oldenburg
Universitaetsklinikum Tuebingen - Hautklinik
RECRUITING
Tübingen
Helios Klinikum Wuppertal - Klinik fuer Dermatologie, Venerologie
RECRUITING
Wuppertal
Israel
Tel Aviv Sourasky Medical Center - Neurosurgery
RECRUITING
Tel Aviv
Tel Aviv Sourasky Medical Center-Derma - 150314762
RECRUITING
Tel Aviv
Italy
Istituto San Gallicano IRCCS - Istituti Fisioterapici Ospitalieri - Parent
RECRUITING
Rome
Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma) - Dip. Medicina - U.O.C. Reumatologia
RECRUITING
Verona
Poland
Centrum Medyczne Plejady
RECRUITING
Krakã³w
Twoja Przychodnia-Szczecinskie Centrum Medyczne Sp. z o. o.
RECRUITING
Szczecin
Pratia Poznan
RECRUITING
Warsaw
Republic of Korea
Chung-ang University Gwangmyeong Hospital
RECRUITING
Seongnam-si
Kyung Hee University Hospital at Gangdong
RECRUITING
Seoul
Romania
S.C Neurocity S.R.L
RECRUITING
Bucharest
Spain
Hospital General de Castellon - Servicio de Reumatologia
RECRUITING
Castellã³n
Hospital Universitario Reina Sofia - Dermatology Dep
RECRUITING
Córdoba
Hospital Universitario La Paz - Internal Medicine Department
RECRUITING
Madrid
Hospital Universitario Rio Hortega - Servicio de Medicina Interna
RECRUITING
Valladolid
Switzerland
Dermatotomi AG
RECRUITING
Weinfelden
IZZ Immunologie-Zentrum Zuerich - Innere Medizin, Allergologie, Immunologie
RECRUITING
Zurich
Taiwan
Kaohsiung Chang Gung Memorial Hospital
RECRUITING
Kaohsiung City
Kaohsiung Veterans General Hospital - Internal Medicine
RECRUITING
Kaohsiung City
United Kingdom
Doncaster Royal Infirmary - Dept of Rheumatology
RECRUITING
Doncaster
Contact Information
Primary
US Medical Information
eMediUSA@emdserono.com
888-275-7376
Backup
Communication Center
service@emdgroup.com
+49 6151 72 5200
Time Frame
Start Date: 2026-04-01
Estimated Completion Date: 2029-05-25
Participants
Target number of participants: 202
Treatments
Experimental: Enpatoran
Placebo_comparator: Placebo
Sponsors
Collaborators: Merck KGaA, Darmstadt, Germany
Leads: EMD Serono Research & Development Institute, Inc.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials